Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GT Biopharma, Inc.GTBP · Entity 7878 | Director · CEO and Director | September 04, 2025 | September 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GT Biopharma, Inc.
Report date September 04, 2025 · Filed September 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-08-19 | Direct | 100,000 |
Reported balance
After 2025-09-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-04 · Grant · Acquired 100,000 · Balance 100,000 F1: The options are fully vested and exercisable. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-08-19 | Direct | 100,000 |
Reported balance
After 2025-09-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-09-04 · Grant · Acquired 100,000 · Balance 100,000 F2: The option vests in four equal quarterly installments beginning on January 1, 2025. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2035-08-19 | Direct | 100,000 |
Reported balance
After 2025-09-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-09-04 · Grant · Acquired 100,000 · Balance 100,000 F3: The option vests in four equal quarterly installments beginning on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The options are fully vested and exercisable.
F2: The option vests in four equal quarterly installments beginning on January 1, 2025.
F3: The option vests in four equal quarterly installments beginning on January 1, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Prairie Operating Co.
Report date May 03, 2023 · Filed May 06, 2023
Section 16 reporting ended · disclosed 2023-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,144,683 |
Ending reported balance
After 2023-05-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-05-03 · Purchase · Acquired 916,112 · Balance 926,112 Row 2 · 2023-05-03 · Grant · Acquired 218,571 · Balance 1,144,683 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2023-10-15 | Direct | 15,000 |
Reported balance
After 2018-10-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-16 · Grant · Acquired 15,000 · Balance 15,000 |
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2024-09-12 | Direct | 30,000 |
Reported balance
After 2019-09-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-09-12 · Grant · Acquired 15,000 · Balance 30,000 |
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2025-08-02 | Direct | 67,500 |
Reported balance
After 2020-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-08-03 · Grant · Acquired 37,500 · Balance 67,500 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2025 Filed Sep 8, 2025 21:45 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001641172-25-026890 · ownership.xml · derivative · entry 3 Breen Michael Martin · CIK 0001863633 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-08-19 F3 · derivative.exercise_date: The option vests in four equal quarterly installments beginning on January 1, 2026. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:45 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001641172-25-026890 · ownership.xml · derivative · entry 2 Breen Michael Martin · CIK 0001863633 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-08-19 F2 · derivative.exercise_date: The option vests in four equal quarterly installments beginning on January 1, 2025. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:45 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $1.33 | $0.00 |
DisclosureSEC source: 0001641172-25-026890 · ownership.xml · derivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director · CEO and Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-08-19 F1 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 23:29 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantCommon Stock | 200,000 | $0.29 | $57,400.00 |
DisclosureSEC source: 0001493152-23-029061 · ownership.xml · nonDerivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director · Executive Chairman/Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 856,218 Read SEC document |
| May 03, 2023 Filed May 6, 2023 01:43 UTC | Prairie Operating Co. CRKR · Entity 7132 | GrantCommon Stock | 218,571 | $0.18 | $38,249.93 |
DisclosureSEC source: 0001493152-23-015707 · ownership.xml · nonDerivative · entry 2 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144,683 Read SEC document |
| May 03, 2023 Filed May 6, 2023 01:43 UTC | Prairie Operating Co. CRKR · Entity 7132 | PurchaseCommon Stock | 916,112 | $0.11 | $99,856.21 |
DisclosureSEC source: 0001493152-23-015707 · ownership.xml · nonDerivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 926,112 Read SEC document |
| April 11, 2023 Filed Apr 11, 2023 22:59 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | PurchaseCommon Stock | 50,000 | $0.50 | $25,000.00 |
DisclosureSEC source: 0001493152-23-011888 · ownership.xml · nonDerivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director · Executive Chairman/Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,218 Read SEC document |
| January 27, 2023 Filed Feb 1, 2023 11:05 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 500,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-23-003230 · ownership.xml · derivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director · Exec Chairman and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: 1/12th of the shares vest on the monthly anniversary of January 1, 2023 until fully vested, subject to full acceleration in the event the reporting person is not re-elected to the board of directors or is removed from the board of directors other than for misconduct, and the reporting person is involuntarily terminated by the registrant. Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:48 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001493152-22-019876 · ownership.xml · derivative · entry 2 Breen Michael Martin · CIK 0001863633 · Director · Exec. Chair. and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-14 Read SEC document |
| July 15, 2022 Filed Jul 20, 2022 01:48 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantCommon Stock | 278,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-019876 · ownership.xml · nonDerivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director · Exec. Chair. and Interim CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 606,218 Read SEC document |
| February 25, 2021 Filed Nov 12, 2021 17:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | Conversion10% Senior Convertible Debenture · Derivative | 30,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001654954-21-012057 · section16.xml · derivative · entry 6 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,859 shares Expires 2021-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Nov 12, 2021 17:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | Conversion10% Senior Convertible Debenture · Derivative | 100,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001654954-21-012057 · section16.xml · derivative · entry 5 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,243 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding until converted. Read SEC document |
| February 25, 2021 Filed Nov 12, 2021 17:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | ConversionCommon Stock | 9,859 | $3.40 | $33,520.60 |
DisclosureSEC source: 0001654954-21-012057 · section16.xml · nonDerivative · entry 3 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2021 Filed Nov 12, 2021 17:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | ConversionCommon Stock | 40,243 | $3.40 | $136,826.20 |
DisclosureSEC source: 0001654954-21-012057 · section16.xml · nonDerivative · entry 2 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Nov 12, 2021 17:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantOption to purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001654954-21-012057 · section16.xml · derivative · entry 4 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-15 F2 · derivative.exercise_date: 1/3rd of the shares vest on February 16, 2021, 2022 and 2023. Read SEC document |
| February 16, 2021 Filed Nov 12, 2021 17:01 UTC | GT Biopharma, Inc. GTBP · Entity 7878 | GrantCommon Stock | 278,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-012057 · section16.xml · nonDerivative · entry 1 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,058 F1 · shares: Represents a grant of shares of restricted stock ("RSAs"). 1/3rd of the RSAs vest on January 13, 2021, 2022 and 2023. Read SEC document |
| August 03, 2020 Filed May 6, 2023 01:43 UTC | Prairie Operating Co. CRKR · Entity 7132 | GrantStock Option (Right to Buy · Derivative | 37,500 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001493152-23-015707 · ownership.xml · derivative · entry 5 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 37,500 shares Expires 2025-08-02 Read SEC document |
| September 12, 2019 Filed May 6, 2023 01:43 UTC | Prairie Operating Co. CRKR · Entity 7132 | GrantStock Option (Right to Buy · Derivative | 15,000 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001493152-23-015707 · ownership.xml · derivative · entry 4 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 15,000 shares Expires 2024-09-12 Read SEC document |
| October 16, 2018 Filed May 6, 2023 01:43 UTC | Prairie Operating Co. CRKR · Entity 7132 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.25 | $0.00 |
DisclosureSEC source: 0001493152-23-015707 · ownership.xml · derivative · entry 3 Breen Michael Martin · CIK 0001863633 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2023-10-15 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.